Novo Nordisk A/S (NVO) Receives ‘Analyst’ Rating

Novo Nordisk A/S (NVO) : 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Novo Nordisk A/S (NVO). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 3 Wall Street Analysts endorse the stock as a Hold with a rating of 3.


Also, Major Brokerage house, JP Morgan downgrades its ratings on Novo Nordisk A/S (NYSE:NVO). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on September 9, 2016.

Novo Nordisk A/S (NYSE:NVO): After opening at $45.99, the stock dipped to an intraday low of $45.86 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $46.47 and the buying power remained strong till the end. The stock closed at $46.24 for the day, a gain of 0.41% for the day session. The total traded volume was 3,050,682. The stocks close on the previous trading day was $46.05.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.